论文部分内容阅读
目的探讨碳酸酐酶Ⅱ(CAⅡ)的表达与结直肠癌(CRC)的发生、发展,以及临床病理特征的关系。方法 Western Blot法检测CAⅡ在12对新鲜配对的CRC和远癌黏膜中的表达。再以免疫组织化学法检测CAⅡ在配对的64对远癌结直肠黏膜和CRC,20个转移淋巴结及27个息肉中的表达,比较各组间表达的差异。分析CAⅡ表达与CRC的部位、分化及临床病理分期间的关系。结果 Western Blot检测显示远癌黏膜CAⅡ/tubulin灰度比为2.48±1.68,癌组织为1.33±1.28,两者差异有统计学意义(P=0.027)。免疫组化显示CAⅡ的表达评分远癌黏膜为(2.81±0.48)分,息肉(包括增生性息肉和腺瘤)为(2.56±0.51)分,CRC为(1.30±0.89)分;按上述3种组织的顺序评分逐步显著降低(P<0.05)。在转移淋巴结中为(1.35±0.67)分,表达与配对原发灶相似(P>0.05)。CAⅡ的表达在不同部位和分化程度的CRC间差异无统计学意义(P>0.05),Ⅲ,Ⅳ期表达与Ⅰ,Ⅱ期无统计学差异(P>0.05)。结论 CAⅡ在CRC中表达的下调,是CRC发生中的早期事件,与分化、分期和转移无关。
Objective To investigate the relationship between the expression of carbonic anhydrase Ⅱ (CA Ⅱ) and the occurrence, development and clinicopathological features of colorectal cancer (CRC). Methods Western Blot was used to detect the expression of CA Ⅱ in freshly paired CRC and distantlymphoma. The expression of CA Ⅱ in paired 64 pairs of distant colorectal mucosa and CRC, 20 metastatic lymph nodes and 27 polyps was detected by immunohistochemistry. The differences among the groups were compared. The relationship between the expression of CA Ⅱ and the location, differentiation and clinical stage of CRC were analyzed. Results Western Blot showed that the ratio of CAⅡ / tubulin in distant mucosa was 2.48 ± 1.68 and 1.33 ± 1.28 in cancerous tissues, the difference was statistically significant (P = 0.027). Immunohistochemistry showed that the expression of CA Ⅱ was (2.81 ± 0.48) in distant mucosa, (2.56 ± 0.51) in polyps (including proliferative polyp and adenoma), and (1.30 ± 0.89) in CRC. According to the above three The order of organization gradually and significantly decreased (P <0.05). It was (1.35 ± 0.67) points in lymph node metastasis, which was similar to the matched primary tumor (P> 0.05). There was no significant difference in the expression of CA Ⅱ between different sites and the degree of differentiation (P> 0.05). There was no significant difference between stage Ⅲ and Ⅳ in stage Ⅰ and stage Ⅱ (P> 0.05). Conclusion The downregulation of CA Ⅱ expression in CRC is an early event in the pathogenesis of CRC, which has nothing to do with differentiation, staging and metastasis.